drugset / Trial / NCT05091099
The Optimal Sequential Therapy After Long Term Denosumab Treatment
RandomizedParallel-groupOpen-labelTreatment
Summary
This study intends to investigate whether Alendronate and Zoledronate can prevent bone mineral density loss after long-term treatment with Denosumab.
Timeline
- Start
- 2022-01-10
- Primary completion
- 2025-11-14
- Completion
- 2025-11-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alendronic Acid | Small molecule | — | — |
| Subject | Zoledronate | Other / unclassified | — | — |